Tenofovir Alafenamide for HIV Preexposure Prophylaxis
- PMID: 32628873
- PMCID: PMC8063139
- DOI: 10.7326/L20-0301
Tenofovir Alafenamide for HIV Preexposure Prophylaxis
Comment on
-
Tenofovir Alafenamide for HIV Preexposure Prophylaxis: What Can We DISCOVER About Its True Value?Ann Intern Med. 2020 Feb 18;172(4):281-282. doi: 10.7326/M19-3337. Epub 2020 Jan 14. Ann Intern Med. 2020. PMID: 31931525 Free PMC article.
-
Tenofovir Alafenamide for HIV Preexposure Prophylaxis.Ann Intern Med. 2020 Jul 7;173(1):77-78. doi: 10.7326/L20-0300. Ann Intern Med. 2020. PMID: 32628874 No abstract available.
References
-
- Chou R, Evans C, Hoverman A, Sun C, Dana T, Bougatsos C, et al. Pre-Exposure Prophylaxis for the Prevention of HIV Infection: A Systematic Review for the U.S. Preventive Services Task Force. Rockville (MD); 2019. - PubMed
-
- Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, et al. Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. Clin Infect Dis. 2020;70(4):687–91. - PMC - PubMed
-
- U.S. Food and Drug Administration. FDA Briefing Information for the August 7, 2019 Meeting of the Antimicrobial Drugs Advisory Committee. https://www.fda.gov/media/129607/download. Accessed on March 12, 2020.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical